Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 401–500 of 780
He, Q., Wei, Y., Qian, Y., & Zhong, M. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.02.003 · Cited by 17
“Rother et al. [ 176 ] 2007 Human Paroxysmal nocturnal hemoglobinuria Eculizumab targeted C5 to effectively treat paroxysmal nocturnal hemoglobinuria, demonstrating the value of complement inhibition.”
BackgroundZong, Y., Miyagaki, M., Yang, M., Zhang, J., Zou, Y., Ohno‐Matsui, K., & Kamoi, K. (2024) · Antibodies · doi:10.3390/antib13040086 · Cited by 19
“Eculizumab is a humanized monoclonal antibody targeting C5 that inhibits the formation of the membrane attack complex (MAC) by blocking the terminal pathway of complement activation [165].”
BackgroundRenal allograft pathology in the sensitized patient
Cornell, L. D. (2013) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283614c5a · Cited by 15
“Unau 1087-2418 2013 Wolters Kluwer Health | Lippincott Williams & Wilk and C5b, also a pro-inflammatory molecule and a component of the membrane attack complex, which can cause cell lysis [34,35].”
BackgroundHope for a rare disease: eculizumab in neuromyelitis optica
Paul, F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70089-9 · Cited by 14
Thrombotic microangiopathies: Similar presentations, different therapies
Appel, G. B. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17001 · Cited by 15
Vaught, A. “. J., Braunstein, E. M., Chaturvedi, S., Blakemore, K. J., & Brodsky, R. A. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1755650 · Cited by 17
“The drug eculizumab contains portions of both IgG2 and IgG4 so it is not thought to easily cross the placenta [27].”
BackgroundMonoclonal antibodies in neuroinflammatory diseases
Klotz, L., & Wiendl, H. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.767329 · Cited by 15
“Eculizumab already demonstrated efficacy in paroxysmal nocturnal hemoglobinemia [75].”
BackgroundPlant biofarming: Novel insights for peptide expression in heterologous systems
Viana, A. A. B., Pelegrini, P. B., & Grossi‐de‐Sá, M. F. (2012) · Biopolymers · doi:10.1002/bip.22089 · Cited by 16
Clinical relevance of lung-restricted antibodies in lung transplantation
Akbarpour, M., Wu, Q., Liu, X., Sun, H., Lecuona, E., Tomic, R., Bhorade, S. M., Mohanakumar, T., & Bharat, A. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.04.016 · Cited by 17
“Since complement inhibition is now possible with FDA approved drugs including Eculizumab [69], further studies to determine whether the activation of specific complement pathways plays a causal role in LRA-mediated lung injury could immediately impact clinical practice (Figure 1C).”
BackgroundStruijf, E. M., De la O Becerra, K. I., Ruyken, M., de Haas, C. J. C., van Oosterom, F., Siere, D. Y., van Keulen, J. E., Heesterbeek, D. A. C., Dolk, E., Heukers, R., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104956 · Cited by 15
“; https://doi.org/10.1101/2023.02.22 .529391 doi: bioRxiv preprint prevents its cleavage by blocking the interaction of C5 with the C5 convertases (14).”
BackgroundInfluentialMuff-Luett, M. A., Sanderson, K., Engen, R. M., Zahr, R. S., Wenderfer, S. E., Tran, C. L., Sharma, S., Cai, Y., Ingraham, S. E., Winnicki, E., et al. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-04965-5 · Cited by 17
Multifaceted Activities of Seven Nanobodies against Complement C4b
Becerra, K. I. D. L. O., Oosterheert, W., van den Bos, R. M., Xenaki, K. T., Lorent, J. H., Ruyken, M., Schouten, A., Rooijakkers, S. H. M., Henegouwen, P. M. P. V. B. E., & Gros, P. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100647 · Cited by 14
The complement model disease paroxysmal nocturnal hemoglobinuria
Schmidt, C. Q., Höchsmann, B., & Schrezenmeier, H. (2024) · European Journal of Immunology · doi:10.1002/eji.202350817 · Cited by 16
“In 2007, the first-in-class complement inhibitor, eculizumab, was approved for the treatment of PNH. Eculizumab is a humanized monoclonal antibody that targets the complement component C5 and thus “only” inhibits the terminal and lytic pathway, which has the greatest inflammatory potential [30].”
The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein
Lee, J., Cho, J. H., Yeo, J., Lee, S. H., Yang, S. H., Sung, Y. C., Kang, J., & Park, C. (2012) · Biologicals · doi:10.1016/j.biologicals.2012.09.001 · Cited by 14
“TNF-dependent cytolytic activity using L929 cells (CCL-1, ATCC) was measured as previously described [18].”
BackgroundMethodRenal involvement in paroxysmal nocturnal haemoglobinuria: a brief review of the literature
Macedo, Ê. S., Filho, S. L. A. P., Pro, J. D. Z., Rolim, V. D. M., Primo, G. D. A. S., Brunetta, D. M., da Silva, H. F., Meneses, G. C., Barroso‐Duarte, F., & Daher, E. D. F. (2018) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.64.12.1139 · Cited by 16
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 15
How doPIG-Amutant paroxysmal nocturnal hemoglobinuria stem cells achieve clonal dominance?
Brodsky, R. A. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.35 · Cited by 14
Lee, J. H., Yeo, J., Park, H. S., Sung, G., Lee, S. H., Yang, S. H., Sung, Y. C., Kang, J., & Park, C. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.09.001 · Cited by 14
IVIG efficacy in CIDP patients is not associated with terminal complement inhibition
Keller, C. W., Quast, I., Dalakas, M. C., & Lünemann, J. D. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.02.001 · Cited by 14
Sokolov, A., Hellerud, B. C., Tønnessen, T. I., Johannessen, E. A., & Mollnes, T. E. (2012) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34348 · Cited by 15
Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics
Garcia, B. L., Skaff, D. A., Chatterjee, A., Hanning, A., Walker, J. K., Wyckoff, G. J., & Geisbrecht, B. V. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601932 · Cited by 14
“Importantly, mAbs against C3b that block the binding of fB have been shown to effectively disrupt AP C3 convertase formation and show promising therapeutic potential in in vitro disease models of PNH and dense deposit disease (17–19).”
BackgroundInfluentialStrohl, W. R. (2011) · Modecular medicine and medicinal · doi:10.1142/9781848166295_0005 · Cited by 14
Habib, A. A., Klink, A. J., Muppidi, S., Parthan, A., Sader, S. C., Balanean, A., Gajra, A., Nowak, R. J., Howard, J. F., & the ELEVATE Study Group (2024) · Journal of Neurology · doi:10.1007/s00415-024-12569-w · Cited by 13
Complement’s involvement in allergic Th2 immunity: a cross-barrier perspective
Thomas, S. A., & Lajoie, S. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188352 · Cited by 15
Complement modulation in solid-organ transplantation
Touzot, M., Obada, E. N., Beaudreuil, S., François, H., & Dürrbach, A. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.001 · Cited by 15
“The presence of a hinge region from human Ig-G2, which does not bind to Fc receptors, and the CH2–CH3 from human Ig-G4 that does not activate complement, is essential for its activity [82].”
BackgroundMany drugs for many targets: novel treatments for complement-mediated glomerular disease
Thurman, J. M. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw228 · Cited by 13
Complement in Non-Antibody-Mediated Kidney Diseases
Angeletti, A., Reyes‐Bahamonde, J., Cravedi, P., & Campbell, K. N. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00099 · Cited by 15
“org July 2017 | Volume 4 | Article 99 eculizumab Eculizumab is the first complement inhibitor approved for clinical use, initially for paroxysmal nocturnal hemoglobinuria (PNH) and subsequently for aHUS (88).”
BackgroundEmerging immunotherapies for autoimmune kidney disease
Foster, M. H., & Ord, J. R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1555569 · Cited by 14
“Eculizumab was bioengineered to minimize immunogenicity and remove IgG effector functions.(79) Safety and efficacy of eculizumab were established in randomized controlled trials of patients with paroxysmal nocturnal hemoglobinuria, a genetic disorder that results in”
BackgroundEculizumab deposits in vessel walls in thrombotic microangiopathy
Cassol, C. A., Brodsky, S. V., Satoskar, A. A., Blissett, A. R., Cataland, S. R., & Nádasdy, T. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.008 · Cited by 13
New anti-complement drugs: not so far away
Thurman, J. M. (2014) · Blood · doi:10.1182/blood-2014-02-555805 · Cited by 13
“Eculizumab, a monoclonal antibody to C5, prevents C5b-9 formation and was approved by the US Food and Drug Administration (FDA) in 2007 for treatment of PNH.4 PNH patients treated with eculizumab require fewer transfusions, have higher quality-of-life indices, and may have a survival benefit.5,6 However, eculizumab do…”
BackgroundInfluentialMechanisms of Complement-Mediated Damage in Hematological Disorders
Taylor, R. P., & Lindorfer, M. A. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.003 · Cited by 14
Ono, M., Ohashi, N., Namikawa, A., Katahashi, N., Ishigaki, S., Tsuji, N., Isobe, S., Iwakura, T., Sakao, Y., Tsuji, T., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0228-17 · Cited by 13
“Eculizumab is a humanized monoclonal antibody against C5 that inhibits the cleavage of C5 into C5a and C5b and suppresses the activation of a late step of the complement cascade (15).”
BackgroundEvolution of compstatin family as therapeutic complement inhibitors
Huang, Y. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437139 · Cited by 13
Gembillo, G., Siligato, R., Cernaro, V., & Santoro, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051261 · Cited by 18
“Prolonged eculizumab therapy was linked to a decrement in hemolysis, lasting over more than 54 months of treatment [148].”
BackgroundPassot, C., Desvignes, C., Ternant, D., Bejan‐Angoulvant, T., Duveau, A.-C., Gatault, P., & Paintaud, G. (2017) · Bioanalysis · doi:10.4155/bio-2017-0070 · Cited by 15
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
Martí-Carvajal, A. J., Anand, V., Cardona, A. F., & Solà, I. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010340 · Cited by 13
Manning, J. E., Anderson, R. M., Hill, A., Zeidan, D., & Ciantar, E. (2021) · Obstetric Medicine · doi:10.1177/1753495x211019899 · Cited by 12
“Eculizumab is a terminal complement inhibitor, which hampers the formation of the membrane attack complex preventing complement-mediated intravascular haemolysis.(6) Large-scale RCTs have demonstrated a significant benefit from the use of eculizumab in non-pregnant women, reducing both symptom burden and complication…”
BackgroundThe case for complement component 5 as a target in neurodegenerative disease
Stennett, A., Friston, K., Harris, C. L., Wollman, A. J. M., Bronowska, A. K., & Madden, K. S. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2177532 · Cited by 12
“C5b undergoes a series of interactions with further complement components to form the membrane attack complex (MAC), a cytolytic pore which then destroys pathogens. ticking over in the body, primed through the hydrolysis of an internal thioester bond, producing C3(H2O), a C3b-like molecule, or by cleavage of C3 to C3b…”
BackgroundInfluentialThe future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 15
Kajana, X., Caridi, G., Bruschi, M., Spinelli, S., Lugani, F., Ghiggeri, G. M., Porta, E. L., Mortari, G., Verrina, E. E., Angeletti, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062789 · Cited by 13
“…is notably underpinned by the exceptional outcomes observed with the anti-C5 blocking antibody eculizumab, which stands as the pioneering complement inhibitor, initially approved for paroxysmal nocturnal hemoglobinuria (PNH) and subsequently for atypical hemolytic uremic syndrome (aHUS) [77].”
Webb, B. J., Healy, R., Child, B., Majers, J., Anand, S., & Gouw, L. G. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12517 · Cited by 12
“To the Editor Eculizumab is a humanized monoclonal antibody that binds with high affinity to complement factor C5, preventing cleavage and thereby inhibiting the terminal complement complex (1).”
BackgroundEculizumab: another breakthrough
Brodsky, R. A. (2017) · Blood · doi:10.1182/blood-2017-01-760496 · Cited by 16
“Eculizumab is a humanized monoclonal antibody that blocks terminal complement by binding to C5 and is the treatment of choice for PNH.(3) Eculizumab virtually eliminates the intravascular hemolysis in PNH patients as evidenced by the rapid”
Thrombotische Mikroangiopathie
Gäckler, A., & Witzke, O. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00487-1 · Cited by 12
Olutogun, T., Cutini, I., Notaro, R., & Luzzatto, L. (2015) · PubMed Central · doi:10.2450/2015.0249-14 · Cited by 12
Experimental models of cardiac transplantation: design determines relevance
Baldwin, W. M., Su, C. A., Shroka, T. M., & Fairchild, R. L. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000113 · Cited by 11
Jeong, S., Noh, Y., Oh, I., Hong, Y., & Shin, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e242 · Cited by 11
Ives, N. J., Woolley, R. L., Saleem, M. A., Moakes, C. A., Waters, A. M., Gilbert, R. D., Jarrett, H., Brettell, E. A., Nash, S., Farmer, L. K., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/rfty4766 · Cited by 12
Sampei, Z., Haraya, K., Gan, S. W., Muraoka, M., Hayasaka, A., Fukuzawa, T., Shida-Kawazoe, M., Tsuboi, Y., Gotoh, A., Obara, N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111679 · Cited by 11
“The extent of the binding interaction was quantified using the Biacore T200 Evaluation Software (Cytiva), with the data normalized to 1 resonance unit (RU) of captured antibody.”
MethodSuccessful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era
Morita, Y., Nishimura, J., Shimada, T., Tanaka, H., Serizawa, K., Taniguchi, Y., Tsuritani, M., Kanakura, Y., & Matsumura, I. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1302-3 · Cited by 11
“Because PNH patients receiving eculizumab are supposed to be susceptible to the meningococcal infection due to the inhibition of C5 [52], the vaccine against meningococcus is routinely administrated prior to the usage of eculizumab [6–9, 11].”
BackgroundComplement cascade and kidney transplantation: The rediscovery of an ancient enemy
Mella, A., Messina, M., Lavacca, A., & Biancone, L. (2014) · World Journal of Transplantation · doi:10.5500/wjt.v4.i3.168 · Cited by 13
Licensed monoclonal antibodies and associated challenges
Khan, A. H., & Sadroddiny, E. (2015) · Human Antibodies · doi:10.3233/hab-150286 · Cited by 12
Targeted therapy in glomerular diseases
Lin, Y.-C., Gau, T.-S., Jiang, Z.-H., Chen, K., Tsai, Y.-T., Lin, K.-Y., Tung, H.-N., & Chang, F. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.06.020 · Cited by 16
Larghi, E. L., Operto, M. A., Torres, R., & Kaufman, T. S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.003 · Cited by 11
Gullipalli, D., Zhang, F., Sato, S., Ueda, Y., Kimura, Y., Golla, M., Miwa, T., Wang, J., & Song, W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800384 · Cited by 11
Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD
Zhu, W., Wang, Z., Hu, S., Gong, Y., Liu, Y., Song, H., Ding, X., Fu, Y., & Yan, Y. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000561 · Cited by 11
“Eculizumab is an approved treatment for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.(19) An open-label trial reported that eculizumab could significantly reduce relapse frequency in patients with NMOSD.”
BackgroundIMGT® Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats
Lefranc, M., & Lefranc, G. (2022) · Antibodies · doi:10.3390/antib11040065 · Cited by 15
“Reduces FcγR binding [128] CDC reduction.”
Hemoglobinúria paroxística noturna: da fisiopatologia ao tratamento
Arruda, M. M. D. A. S., Arrais‐Rodrigues, C., Yamamoto, M., & Figueiredo, M. S. (2010) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302010000200022 · Cited by 11
Ye, Q., Gao, W., Feng, J., Li, X., Li, J., Yang, F., Li, L., Zi, M., Wu, X., Gao, H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71185 · Cited by 11
Troise, D. E., Allegra, C., Cirolla, L. A., Mercuri, S., Infante, B., Castellano, G., & Stallone, G. (2025) · Antioxidants · doi:10.3390/antiox14010066 · Cited by 11
Wang, H., Nugteren, S., Groenland, R. J., van der Meulen, S., Kapsenberg, H., Gstöttner, C., Domínguez‐Vega, E., van Hamburg, J. P., Tas, S. W., Toes, R. E. M., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.06.2130 · Cited by 10
Lorenzen, J. M., Menne, J., Schmidt, B. M. W., Schmidt, M., Martino, F., Dietrich, R. A., Samiri, S., Worthmann, H., Heeren, M., Weißenborn, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047215 · Cited by 10
“This prevents the generation of the terminal complement complex C5b–C9 [21].”
BackgroundCellular changes in eculizumab early responders with generalized myasthenia gravis
Li, Y., Yi, J. S., Howard, J. F., Chopra, M., Russo, M. A., & Guptill, J. T. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108830 · Cited by 10
Advances in Antibody-Based Therapeutics for Cerebral Ischemia
Sun, J., Yen, T., Jan, J., Mwale, P. F., Teng, R.-D., Taliyan, R., Hsieh, C.-T., & Yang, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010145 · Cited by 12
“Eculizumab blocks the terminal complement protein (C5) stimulation pathway by interacting with C5 with strong affinity and specificity [72].”
Nishimura, J., Soubret, A., Arase, N., Buatois, S., Hotta, M., Charoin, J., Ito, Y., Sreckovic, S., Takamori, H., Bucher, C. M., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2851 · Cited by 10
“3 In patients with PNH, C5 blockade reduces intravascular hemolysis, the requirement for red blood cell transfusions, the risk of thrombosis, and mortality.(4,5) However, treatment limitations include extravascular hemolysis, pharmacokinetic (PK) or pharmacodynamic (PD) breakthrough hemolysis due to nonsustained C5 in…”
BackgroundSchaap, C., Heubel-Moenen, F. C. J. I., Nur, E., Bartels, M., van der Heijden, O. W. H., de Jonge, E., Preijers, F. W. M. B., Blijlevens, N. M. A., Langemeijer, S. M. C., & the Dutch PNH Working Group (2023) · European Journal Of Haematology · doi:10.1111/ejh.13946 · Cited by 12
“Notwithstanding its effectiveness, treatment with eculizumab can cause major complications, the most important being the risk of lifethreatening infections with encapsulated bacteria, including meningococcal disease.(1,5,10,19) Moreover, eculizumab is one of world's most expensive drugs and costs approximately €325 00…”
BackgroundKuhn, A., Riegger, J., Teixeira, G. Q., Huber-Lang, M. S., Lambris, J. D., Neidlinger‐Wilke, C., & Brenner, R. E. (2023) · Cells · doi:10.3390/cells12060887 · Cited by 11
“The antibody inhibits cleavage of C5 into the anaphylatoxin C5a and C5b, the initial component of TCC assembly, thereby blocking the terminal pathway of the complement (Figure 1) [26].”
BackgroundResultInfluentialPitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review
Mocanu, A., Bogos, R. A., Lazaruc, T. I., Cianga, A. L., Lupu, V. V., Ioniuc, I. K., Alecsa, M., Lupu, A., Ivanov, A. V., Miron, I. C., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13071228 · Cited by 11
“Eculizumab functions by blocking the generation of proinflammatory C5a and C5b9, through binding with high affinity to C5 complement protein [29].”
BackgroundL’hémoglobinurie paroxystique nocturne
de Latour, R. P., Amoura, Z., & Socié, G. (2009) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.12.020 · Cited by 10
Complement in hemolytic anemia
Brodsky, R. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.385 · Cited by 12
Antibodies against complement-regulatory proteins on platelets in immune thrombocytopenia
Unterberger, U., Eichelberger, B., Ulz, A., & Panzer, S. (2016) · Platelets · doi:10.1080/09537104.2016.1235686 · Cited by 10
“of the potential use of well-established, as well as recently developed, therapeutics targeting complement components [25,26].”
BackgroundSong, A.-Y., Kim, H., Kim, J. M., Hwang, S., Ko, D., & Kim, H. S. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08986 · Cited by 10
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
Mimori, M., Komatsu, T., Maku, T., Mitsumura, H., & Iguchi, Y. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05922-2 · Cited by 10
“In addition, since C5 blockade by eculizumab occurs relatively downstream in the complement cascade, it does not impair the immunoprotective functions of C3bmediated opsonization and immune complex clearance [7].”
BackgroundRare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria
Prata, P. H., Galimard, J., de Fontbrune, F. S., Duval, A., Vieira-Martins, P., Roncelin, S., Debureaux, P.-É., Leprêtre, A., Larcher, L., Birsen, R., et al. (2023) · Blood · doi:10.1182/blood.2022017019 · Cited by 12
Kichloo, A., Chugh, S. S., Gupta, S., Pandav, J., & Chander, P. N. (2019) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709619842905 · Cited by 10
“Eculizumab is a monoclonal antibody that binds to C5 and inhibits its breakdown to C5a and C5b and therefore prevents subsequent formation of the membrane attack complex (MAC).(28,29) The feared complications of hemodialysis in complement-related aHUS can also be prevented by placing the patient on eculizumab during t…”
BackgroundParoxysmal Nocturnal Hemoglobinuria
Antonio, M. (2012) · InTech eBooks · doi:10.5772/29918 · Cited by 10
“1-mAb, Soliris®, Alexion Pharmaceuticals) is a humanized monoclonal antibody (mAb) (Rother et al 2007) derived from the murine anti-human C5 mAb; it specifically binds the terminal complement component 5, thereby inhibiting its cleavage to C5a and C5b (Matis & Rollins 1995).”
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. B. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1488c · Cited by 10
Sonnentag, S. J., Dopler, A., Kleiner, K., Garg, B. K., Mannes, M., Späth, N., Akilah, A., Höchsmann, B., Schrezenmeier, H., Anliker, M., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105784 · Cited by 10
Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation
Sun, Q., Song, S., Ma, J., Li, D., Wang, Y., Yang, Z., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383936 · Cited by 10
“The complement system plays a crucial role in innate immunity and immune regulation, protecting against infections and participating in various physiological and pathological processes (59).”
BackgroundNoninvasive Detection of Complement Activation Through Radiologic Imaging
Thurman, J. M., & Rohrer, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_19 · Cited by 11
Current and Upcoming Treatment Modalities in Myasthenia Gravis
Ramaswamy, S. B., Singh, S., Hooshmand, S., Cho, J., Sweeney, M., & Govindarajan, R. (2021) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000377 · Cited by 9
Atypical hemolytic-uremic syndrome: clinical presentation, diagnosis and treatment
Korotchaeva, Y. V., Kozlovskaya, N. L., Demyanova, K. A., Alexeeva, M., Вячеславович, С. А., & Moiseev, S. (2022) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2022-2-43-50 · Cited by 9
Gabrili, J. J. M., Villas-Boas, I. M., Pidde, G., Squaiella‐Baptistão, C. C., Woodruff, T. M., & Tambourgi, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113333 · Cited by 10
“The standard procedure for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms is the humanized monoclonal antibody eculizumab (Soliris), which binds to C5 and blocks the terminal complement pathway and was approved in 2007 [59,60].”
BackgroundChen, J. Y., Zhang, L., Luo, L., Yang, M., Chen, Y., & Lin, F. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109678 · Cited by 9
Chattopadhyay, S., Lionel, S. A., Selvarajan, S., Devasia, A. J., Korula, A., Kulkarni, U. P., Aboobacker, F. N., Lakshmi, K. M., Srivastava, A., Mathews, V., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05621-2 · Cited by 12
Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition
Varela, J. C., & Brodsky, R. A. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.842896 · Cited by 9
Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody
Kernstock, R. M., Sperinde, G. V., Finco, D., Davis, R., & Montgomery, D. L. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00440-5 · Cited by 9
Röth, A., Araten, D. J., Larratt, L. M., Kulasekararaj, A. G., Maciejewski, J. P., Wilson, A., Gustovic, P., & Kanakura, Y. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13485 · Cited by 10
Safety of current treatments for paroxysmal nocturnal hemoglobinuria
Lee, S., & Lee, J. W. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1857723 · Cited by 10
Successful Use of Eculizumab in a Pediatric Patient Treated for Paroxysmal Nocturnal Hemoglobinuria
Bauters, T. G. M., Bordon, V., Robays, H., Benoit, Y., & Dhooge, C. (2012) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318258079a · Cited by 9
Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria
Keating, G. M., Lyseng-Williamson, K. A., & McKeage, K. (2012) · BioDrugs · doi:10.2165/11208420-000000000-00000 · Cited by 9
“The components of complement proximal to C5, which are necessary for opsonization of micro-organisms and clearance of immune complexes, remain intact.([2])”
BackgroundInfluentialImmunosuppression-state-of-the-art
Eisen, H. J. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000119 · Cited by 9
Treatment of atypical uraemic syndrome in the era of eculizumab
Frémeaux‐Bacchi, V. (2012) · Clinical Kidney Journal · doi:10.1093/ckj/sfr177 · Cited by 9
“Eculizumab (Soliris; Alexion) is a humanized monoclonal antibody indicated for the treatment of paroxysmal nocturnal haemoglobinuria [11].”
BackgroundComplement Factor H: Using Atomic Resolution Structure to Illuminate Disease Mechanisms
Barlow, P. N., Hageman, G. S., & Lea, S. M. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78952-1_10 · Cited by 13
“Importantly, the first complement pathway-directed therapeutic, a humanized monoclonal antibody directed against complement component C5 (Eculizumab; Soliris) was approved in March 2007 for use in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a debilitating disease characterized by chronic complement-med…”
BackgroundParoxysmal nocturnal hemoglobinuria
Loschi, M. L., de Latour, R. P., & Socié, G. (2013) · Hématologie · doi:10.1684/hma.2013.0843 · Cited by 9
Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin
Shiga, Y., Murata, D., Sugimoto, A., Oshima, Y., Tada, M., Ishii‐Watabe, A., Imai, K., Tomii, K., Takeuchi, T., Kagaya, S., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00221 · Cited by 10
Chemical Approaches to Modulating Complement-Mediated Diseases
Iyer, A., Xu, W., Reid, R. C., & Fairlie, D. P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00882 · Cited by 9
Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases
Herle, K. V., Behne, J. M., Herle, A. J. V., Blaschke, T. F., Smith, T. J., & Yeaman, M. R. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134628 · Cited by 11
Rajagopal, V., Leksa, N. C., Gorham, R. D., Jindal, S., Nair, S., Knockenhauer, K. E., Chan, J., Byun, T. S., Mercadante, C. J., Moore, S. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009028 · Cited by 8
Biophysical evaluation of hybrid Fc fusion protein of hGH to achieve basal buffer system
Kim, N. A., An, I. B., Lim, H. S., Yang, S. I., & Jeong, S. H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.055 · Cited by 8
Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report
Walsh, T., Bean, H., & Kaplan, R. B. (2017) · Infection · doi:10.1007/s15010-017-1090-4 · Cited by 8
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.